Cannabis Science Targets Successful Autism Treatments and Brings Family Autism Advocate Mieko Hester-Perez on Its Scientific Advisory Board
Mieko Leads the Charge for Autism Treatment Advocacy as CBIS Initiates Cannabinoid Efficacy Testing to Spotlight Successful Treatments
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced its next critical ailment target is autism and brings Mieko Hester-Perez on its Scientific Advisory Board to lead this charge. Mieko gained significant recognition for bringing her son's success with medical cannabis to the public and birthing the significant "Joey's Strain." The Company has begun preliminary protocols to initiate formal studies with Mieko on autism in adults and children spotlighting successful treatments using cannabinoids.
Please visit http://www.miekosblog.com to watch and learn from Mieko's incredible journey with her son Joey. Mieko used medical cannabis to treat her son "Joey" with autism symptoms, and has seen great progress since starting the treatment. As an autism advocate for the new cannabis patient base special needs families, Mieko has co-founded The Unconventional Foundation for Autism, http://UF4A.org, an informational website. She has even received Congressional Honors for her community service work with special needs children.
"When I decided to go public with my son's success with medical cannabis for autism I was invited on FOX Morning News, The Doctors Show, The Dr. Juan Rivera Show, NBC syndicates, CBS, Good Morning America with Diane Sawyer, and 'Inspiring Parents' on ABC's 20/20 special segments. I've been privileged to gracefully bridge two misunderstood communities with the help of High Times, Autism Spectrum Magazine, and numerous publications as a pioneer to these ground breaking cannabinoid treatments," stated Ms. Hester-Perez.
As a board member for NORML's Woman's Alliance, Mieko Hester-Perez is a proven, knowledgeable, and key figure in the legal cannabis arena. Ms. Hester-Perez on a national platform remains a valuable source of information and support for parents with children requesting cannabinoid treatments until further laws are passed for special needs families who have exhausted all other treatment options. Since becoming a public figure standing on the front lines for special needs families she continues to provide effective navigation guidance to families on this safe, natural, and effective cannabis treatment.
"I am excited we are moving forward with Cannabis Science. In a recent event for Ron Dellums, the CBIS team met in California to discuss its progress on various initiatives. I was fortunate to be in that meeting with some of our key people, such as Ron Dellums, Dr. Allen Herman our CMO, Mel Foote, Mr. Dabney, along with a few others. I am very proud to be a part of this team; it gives me extra strength in multiple areas to move forward to reach my goals of providing continued autism treatments and education for children and their families worldwide, and I firmly believe the Cannabis Science Team is going to help me accomplish these goal immediately and provide some of the tools for me to move forward beyond my expectations. I plan to leverage Cannabis Science's combined experience and fast track my 'Joey's Experience' into a formal study that can positively impact families going through it. We are providing valuable education and real time access to information based on what I have been going through for many years," concludes, Ms. Hester-Perez.
Mother Gives Son Marijuana To Treat His Autism - ABC News
Mother Says Marijuana 'Saved Life' of Autistic Son http://www.ladybud.com/2015/02/02/joeys-strain-cannabis-created-for-symptoms-related-to-autism/
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.